TY - THES A1 - Kraich, Michael T1 - Strukturelle und funktionelle Untersuchungen der Interaktion zwischen Ligand und Rezeptor im Interleukin-4- und Interleukin-13-System T1 - Structural and functional studies of the interaction between ligand and receptor in the interleukin-4 and interleukin-13 system N2 - Interleukin-4 (IL-4) und Interleukin-13 (IL-13) sind bedeutende Regulatorproteine des Immunsystems. Sie spielen eine entscheidende Rolle bei der Entstehung und dem Verlauf von allergischen Erkrankungen, wie z.B. Asthma. Um ihre Signale in die Zielzelle zu transduzieren, kann von beiden Zytokinen der gleiche Zelloberflächenrezeptor verwendet werden, wodurch sich die überlappenden, biologischen Funktionen erklären lassen. Dieser gemeinsam genutzte Rezeptor ist aus den beiden Untereinheiten IL-4Ralpha; und IL-13Ralpha1 aufgebaut. Da IL-4 und IL-13 auf Aminosäureebene nur etwa 25% Sequenzidentität besitzen und stark unterschiedliche Affinitäten zu den beiden Rezeptorketten besitzen, stellt sich die Frage, durch welchen molekularen Erkennungsmechanismus, die Affinität und die Spezifität der Ligand-Rezeptor-Interaktion unabhängig voneinander reguliert werden kann. In dieser Arbeit gelang es, rekombinante Expressions- und Aufreinigungsstrategien für IL-13 und die extrazellulären Domänen der Rezeptorketten IL-13Ralpha1 und IL-13Ralpha2 zu entwickeln. Dadurch war es mögliche, eine breite Mutations-/Interaktionsanalyse der IL-13Ralpha1-Kette durchzuführen.Es konnte gezeigt werden, dass die N-terminale FnIII-ähnliche Domäne von IL-13Ralpha1 sowohl an der Bindung von IL-13 als auch an der Interaktion mit IL-4 beteiligt ist. Im funktionellen Bindeepitop der IL-13Ralpha1-Kette wurden die Aminosäurereste Arg84, Phe253 und Tyr321 als Hauptbindungsdeterminanten für die Interaktion mit IL-13 identifiziert. Durch die Interaktionsstudien der IL-13Ralpha1-Varianten mit IL-4 wurde gezeigt, dass diese Hauptbindungsdeterminanten auch für die niederaffine Bindung von IL-4 von größter Bedeutung sind. Die funktionellen Bindeepitope für IL-4 und IL-13 auf der IL-13Ralpha1-Kette sind nahezu identisch und überlappen in einem großen Bereich. Aufgrund der Ergebnisse aus der Mutagenesestudie war es möglich, ein Strukturmodell der extrazellulären Domäne der IL-13Ralpha1-Kette zu erstellen. Darin wird eine neuartige Orientierung der N-terminalen FnIII-Domäne und deren Beteiligung an der Ligandeninteraktion dargestellt. Mit Hilfe des Strukturmodells gelang es, neue Aminosäurerest auf der Oberfläche von IL-13 zu identifizieren, die an der Bindung zu IL-13Ralpha1 beteiligt sind, was die Relevanz des Strukturmodells weiter unterstreicht. In einem weiteren Teil dieser Arbeit wurde versucht, den molekularen Mechanismus aufzuklären, durch den es den superagonistischen IL-4-Varianten T13D und F82D gelingt, mit dreifach höherer Affinität an die IL-4Ralpha-Kette zu binden, als wildtypischer Ligand. Durch strukturelle und funktionelle Untersuchungen wurde gezeigt, dass der Affinitätssteigerung ein indirekter Mechanismus zugrunde liegt, bei dem eine Konformationsänderung und die Fixierung der Arg85-Seitenkette von IL-4 zur Ausbildung von zusätzlichen Ligand-Rezeptor-Interaktionen führt. Das Bindeepitop zwischen IL-4 und der IL-4Ralpha-Kette besitzt eine modulare Architektur aus drei unabhängig voneinander agierenden Interaktionsclustern. Bei der Interaktion von wildtypischem IL-4 mit IL-4Ralpha tragen nur zwei dieser Cluster in signifikanter Weise zur freien Bindeenergie bei. Im Falle der superagonistischen IL-4-Varianten ist jedoch auch das dritte Cluster an der Generierung von zusätzlicher, freier Bindeenergie beteiligt, wodurch die Affinität zwischen Ligand und Rezeptor erhöht wird. Damit stellt der modulare Aufbau der Interaktionsfläche zwischen IL-4 und der IL-4Ralpha-Kette möglicherweise einen Mechanismus dar, über den Proteine die Affinität von Wechselwirkungen über einen großen Bereicht variieren können, ohne dabei Spezifität einzubüssen. Da IL-4 und IL-13 als interessante Zielmoleküle für die Therapie von allergischen und asthmatischen Erkrankungen erkannt worden sind, können die in der vorliegenden Arbeit gewonnenen Informationen über den Bindemechanismus und die Einblicke in den molekularen Charakter der Interaktion zwischen den beiden Zytokinen und ihren spezifischen Rezeptorketten dabei helfen, neuartige und hoch spezifische, inhibitorische Moleküle zu entwickeln. N2 - Interleukin-4 (IL-4) and Interleukin-13 (IL-13) are important regulatory proteins of the immune system. They play a key role in the development and the progression of allergic diseases like asthma. For signal transduction into the target cell, both cytokines can use an identical cell surface receptor, which is an explanation for many overlapping biological functions of IL-4 and IL-13. This common receptor consists of the two subunits IL-4Ralpha and IL-13Ralpha1. Because IL-4 and IL-13 share only 25% sequence identity on the amino acid sequence level and because they show very different affinities to the two receptor chains, the question has to be raised, by which molecular recognition mechanism it is possible to regulate affinity and specificity of the ligand-receptor-interaction independently. In the course of this work recombinant expression and purification strategies for IL-13 and the extracellular domains of IL-13Ralpha1 and IL-13Ralpha2 were established. Therefore it was possible to perform a broad mutagenesis and interaction analysis of the IL-13Ralpha1 chain. It was shown, that the N-terminal FnIII-like domain of IL-13Ralpha1 participates in the binding of IL-13 as well as in the interaction with IL-4. As part of the functional epitope the amino acid residues Arg84, Phe253 and Tyr321 were identified to be main binding determinants for the interaction with IL-13. By carrying out interaction studies with IL-4 it could be demonstrated, that the same residues are also from great importance for the low affinity binding of IL-4. The functional epitopes for the binding of IL-4 and IL-13 are almost identical and are overlapping in a large area. Due to the results of the mutagenesis study it was possible to generate a structural model of the extracellular domain of the IL-13Ralpha1 chain. A key feature of this model is the novel orientation of the N-terminal FnIII-like domain and its involvement in ligand binding. According to the modelled structure new residues in IL-13 could be identified, that participate in the interaction with the IL-13Ralpha1. This further underlines the relevance of the shown structural model of the extracellulardomain of the IL-13Ralpha1 chain. In a different part of this work it was tried to elucidate the molecular mechanism, which enables the super-agonistic IL-4 variants T13D and F82D bind IL-4Ralpha with three times higher affinity than wildtype IL-4. With the help of structural und functional analysis it could be shown, that an indirect mechanism leads to the gain of affinity. A conformational change in and the fixation of the Arg85 side chain in IL-4 result in the formation of additional interactions between ligand and receptor. The binding interface between IL-4 and IL-4Ralpha exhibits a modular architecture consisting of three independently acting interaction clusters. For the binding of wild-type IL-4 to the IL-4Ralpha chain only two of the three clusters contribute a significant amount to the overall free binding energy. In the case of the super-agonistic IL-4 variants all three interaction clusters are used to generate additional free binding energy and to increase the affinity between ligand and receptor. Therefore the modular design of the IL-4/IL-4Ralpha interaction interface probably represents a mechanism, which enables proteins to alter the affinity of interactions over a broad range without loosing specificity. Because IL-4 and IL-13 were discovered as promising targets for the therapy of allergic and asthmatic diseases, the acquired information about the binding mechanism and the molecular characteristics of the interaction between the cytokines IL-4 and IL-13 and their specific receptor chains may help to design novel and highly specific inhibitory molecules. KW - Renaturierung KW - Ligand KW - Biochemie KW - Interleukin 4 KW - Interleukin 13 KW - Interaktion KW - Rezeptor KW - Immunologie KW - Allergie KW - Allerg KW - Proteinbiochemie KW - BIAcore KW - Oberflächenplasmonresonanz (SPR) KW - Strukturbiologie KW - interleukin-4 KW - interleukin-13 KW - protein interaction KW - BIAcore KW - structural biology Y1 - 2008 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-27655 ER - TY - JOUR A1 - Schwarz, Klaus A1 - Hameister, Horst A1 - Gessler, Manfred A1 - Grzeschik, Karl-Heinz A1 - Hansen-Hagge, Thomas E. A1 - Bartram, Claus R. T1 - Confirmation of the localization of the human recombination activating gene 1 (RAG1) to chromosome 11p13 N2 - The human recombination activating gene 1 (RAGl) has previously been mapped to chromosomes 14q and 11 p. Here we confirm the chromosome 11 assignment by two independent approaches: autoradiographic and fluorescence in situ hybridization to metaphase spreads and analysis of human-hamster somatic cell hybrid DNA by the polymerase chain reaction (PCR) and Southern blotting. Our results unequivocally localize RAG1 to llp13. KW - Biochemie Y1 - 1994 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-59136 ER - TY - JOUR A1 - Schwartz, Faina A1 - Neve, Rachel A1 - Eisenman, Robert A1 - Gessler, Manfred A1 - Bruns, Gail T1 - A WAGR region gene between PAX-6 and FSHB expressed in fetal brain N2 - Developmental delay or mental retardation is a frequent component of multi-system anomaly syndromes associated with chromosomal deletions. Isolation of genes involved in the mental dysfunction in these disorders should define loci important in brain formation or function. We have identified a highly conserved locus in the distal part of 11 p 13 that is prominently expressed in fetal brain. Minimal expression is observed in a number of other fetal tissues. The gene maps distal to PAX-6 but proximal to the loci for brain-derived neurotrophic factor (BDNF) and the beta subunit of follicle stimulating hormone (FSHB), within a region previously implicated in the mental retardation component of some WAGR syndrome patients. Within fetal brain, the corresponding transcript is prominent in frontal, motor and primary visual cortex as weil as in the caudate-putamen. The characteristics of this gene, including the striking evolutionary conservation at the locus, suggest that the encoded protein may function in brain development. KW - Biochemie Y1 - 1994 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-59125 ER - TY - JOUR A1 - Müller, T. A1 - Dieckmann, T. A1 - Sebald, Walter A1 - Oschkinat, H. T1 - Aspects of receptor binding and signalling of interleukin-4 investigated by site-directed mutagenesis and NMR spectroscopy N2 - Cytokines are hormones that carry information from ceJI to ceH. This information is read from their surface upon binding to transmembrane receptors and by the subsequent initiation of receptor oligomerization. An inftuence on this process through mutagenesis on the hormone surface is highly desirab)e for medical reasons. However, an understanding of hormone-receptor interactions requires insight into the structural changes introduced by the mutations. In this line structural studies on human TL-4 and the medically important IL-4 antagonists YI24D and Y124G are presented. The site a.round YI24 is an important epitope responsible for the a.bility of 11-4 t.o ca.use a signal in the target cells. It is shown that the local main-chain structure around residue 124 in the variants remains unchanged. A strategy is presented here which allows the study of these types of proteins and their variants by NMR which does not require carbon Iabeiied sa.mples. KW - Biochemie KW - Interleukin-4 KW - protein structure KW - NMR KW - signal transduction Y1 - 1994 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-62444 ER - TY - JOUR A1 - Müller, T. A1 - Sebald, Walter A1 - Oschkinat, H. T1 - Antagonist design through forced electrostatic mismatch N2 - No abstract available KW - Biochemie Y1 - 1994 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-62408 ER - TY - JOUR A1 - Reusch, P. A1 - Arnold, S. A1 - Heusser, C. A1 - Wagner, K. A1 - Weston, B. A1 - Sebald, Walter T1 - Neutralizing monoclonal antibodies define two different functional sites in human interleukin-4 N2 - Human interleukin-4 (IL-4) is a small four-helix-bundle protein which is essential for organizing defense reactions against macroparasites, in particular helminths. Human IL-4 also appears to exert a pathophysiological role during various IgE-mediated allergic diseases. Seven different monoclonal antibodies neutralizing the activity of human IL-4 were studied in order to identify functionally important epitopes. A collection of 41 purified IL-4 variants was used to analyse how defined amino acid replacements affect binding affinity for each individual mAb. Specific amino acid positions could be assigned to four different epitopes. mAbs recognizing epitopes on helix A and/or C interfered with IL-4 receptor binding and thus inhibited IL-4 function. However, other mAbs also inhibiting IL-4 function recognized an epitope on helix D of IL-4 and did not inhibit IL-4 binding to the receptor protein. One mAb, recognizing N-terminal and C-terminal residues, partially competed for binding to the receptor. The results of these mAb epitope analyses confirm and extend previous data on the functional consequences of the amino acid replacements which showed that amino acid residues in helices A and C of IL-4 provide a binding site for the cloned IL-4 receptor and that a signalling site in helix D interacts with a further receptor protein. KW - Biochemie Y1 - 1994 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-62418 ER - TY - JOUR A1 - Demchuk, E. A1 - Mueller, T. A1 - Oschkinat, H. A1 - Sebald, Walter A1 - Wade, R. C. T1 - Receptor binding properties of four-helix-bundle growth factors deduced from electrostatic analysis N2 - Hormones of the hematopoietin class mediate signal transduction by binding to specific transmembrane receptors. Structural data show that the human growth hormone (hGH) forms a complex with a homodimeric receptor and that hGH is a member of a class of hematopoietins possessing an antiparallel 4-a-helix bundle fold. Mutagenesis experiments suggest that electrostatic interactions may have an important influence on hormonereceptor recognition. In order to examine the specificity of hormone-receptor complexation, an analysis was made of the electrostatic potentials of hGH, interleukin-2 (IL-2), interleukin-4 (IL-4), granulocyte colony-stimulating factor (G-CSF), granulocyte-macrophage colony-stimulating factor (GM-CSF), and the hGH and IL-4 receptors. The binding surfaces of hGH and its receptor, and of IL-4 and its receptor, show complementary electrostatic potentials. The potentials of the hGH and its receptor display approximately 2-fold rotational symmetry because the receptor subunits are identical. In contrast, the potentials of GM-CSF and IL-2 Iack such symmetry, consistent with their known high affinity for hetero-oligomeric receptors. Analysis of the electrostatic potentials supports a recently proposed hetero-oligomeric model for a high-affinity IL-4 receptor and suggests a possible new receptor binding mode for G-CSF; it also provides valuable information for guiding structural and mutagenesis studies of signal-transducing proteins and their receptors. KW - Biochemie KW - cytokines KW - electrostatic potential KW - hematopoietic receptors KW - human growth factor KW - interleukins KW - molecular recognition Y1 - 1994 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-62424 ER - TY - JOUR A1 - Lehrnbecher, T. A1 - Poot, M. A1 - Orscheschek, K. A1 - Sebald, Walter A1 - Feller, A. C. A1 - Merz, H. T1 - Interleukin 7 as interleukin 9 drives phytohemagglutinin-activated T cells through several cell cycles; no synergism between interleukin 7, interleukin 9 and interleukin 4 N2 - The effects of the interlenkins IL-7 and IL-9 on cell cycle progression were investigated by conventional [3H]thymidine incorporation and by the bivariate BrdU/Hoechst technique. 8oth IL· 7 and IL-9 drive phytohemagglutinin-activated T cells through more than one cell cycle, but IL-7 wasmorepotent on cell cycle progression than IL-9. Neither synergistic nor inhibitory effects were seen between various combinations of the lymphokines IL-7, IL-9 and IL-4 compared to each lymphokine alone. When T cells are activated with phytohemagglutinin for 3 days, all or most IL-4 responsive cells respond to IL-7 as weil, whereas only a part of IL-7 responders are IL-4 responders. In contrast, when T cells are activated with phytohemagglutinin for 7 days, the quantitative data of the cell cycle distribution soggest that the population of IL-7 responders is at least an overlapping, if not a real subset of the population of the IL-4 responders. KW - Biochemie Y1 - 1994 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-62438 ER - TY - JOUR A1 - Kübler, N. A1 - Reuther, J. A1 - Kirchner, T. A1 - Pfaff, M. A1 - Müller-Hermelink, H. K. A1 - Albert, R. A1 - Sebald, Walter T1 - IgG monoclonal antibodies that inhibit osteoinductivity of human bone matrix-derived proteins (hBMP/NCP) N2 - Monoclonal hBMP/NCP (human bone morphogenetic protein anrl associaterl noncollagenous proteins) antiborlies of the lgG class were prorlucerl. In vitro, 12 of 19 hBMP/NCP antiborlies showerl functional inhibition of hBMP/ NCP-induced chondroneogenesis in a neonatal muscle tissue assay. Inducing factors were characterized by their inhibiting antibodies with immunoblotting. Several peptide factors seem to be involved in the cascade of inducerl chondro- and osteogenesis. KW - Biochemie KW - bone morphogenetic proteins KW - neutralizing antibodies KW - cartilage induction Y1 - 1994 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-62388 ER - TY - JOUR A1 - Tony, H. P. A1 - Shen, B. J. A1 - Reusch, P. A1 - Sebald, Walter T1 - Design of human interleukin-4 antagonists inhibiting interleukin-4-dependent and interleukin-13-dependent responses in T-cells and B-cells with high efficiency N2 - Human interleukin-4 possesses two distinct sites for receptor activation. A signaHing site, comprising residues near the C-terminus on helix D, determines the efficacy of interleukin-4 signal transduction without affecting the binding to the interleukin-4 receptor a subunit. A complete antagonist and a series of low-efficacy agonist variants of human interleukin-4 could be generated by introducing combinations of two or three negatively charged aspartic acid residues in this site at positions 121, 124, and 125. One of the double variants, designated [R121D,Y124D]interleukin-4, with replacements of böth Arg121 and Tyr124 by aspartic acid residues was completely inactive in all analysed cellular responses. The loss of efficacy in [R121D,Y124D]interleukin-4 is estimated to be larger than 2000-fold. Variant [R121D,Y124D]interleukin-4 was also a perfect antagonist for inhibition of interleukin-13-dependent responses in B-cells and the TF-1 cellline with a K\(_i\) value of approximately 100 pM. In addition, inhibition of both interleukin-4-induced and interleuk.in-13- induced responses could be obtained by monoclonal antibody X2/45 raised against interleukin-4Rm the extracellular domain of the interleuk.in-4 receptor a subunit. These results indicate that efficient interleukin-4 antagonists can be designed on the basis of a sequential two-step activation model. In addition, the experiments indicate the functional participation of the interleukin-4 receptor a subunit in the interleukin-13 receptor system. KW - Biochemie Y1 - 1994 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-62394 ER -